The High Health Authority Has Refused Access to Vasopressin for Septic Shock: Patients Are not Being Given the Best Possible Chance!

Authors

  • D. Annane Président du Syndicat national des médecins réanimateurs des hôpitaux publics, service de médecine intensive et réanimation, U1173 Inserm/UVSQ, UFR Simone-Veil-Santé, université Paris-Saclay, hôpital Raymond-Poincaré (AP–HP)
  • P.-E. Bollaert Service de médecine intensive et réanimation, CHRU de Nancy, hôpital Central
  • A. Demoule Service de pneumologie, unité de médecine intensive et réanimation, médecine intensive et réanimation, hôpital universitaire Pitié-Salpêtrière, Sorbonne Université-Médecine, bâtiment Eole
  • J.-P. Mira Président du Conseil national professionnel–médecine intensive et réanimation, groupe hospitalier Paris-Centre, université de Paris, AP–HP
  • X. Monnet Service de réanimation-médecine intensive, faculté de médecine Paris-Sud, hôpital de Bicêtre, hôpitaux universitaires Paris-Sud, université Paris-Sud
  • J.-L. Teboul Service de médecine-intensive et réanimation, faculté de médecine Paris-Sud, université Paris-Sud, hôpital Bicêtre, hôpitaux universitaires Paris-Sud, AP–HP
  • A. Vieillard-Baron Inserm UMR 1018, équipe 5 Rein-Coeur, médecine intensive et réanimation, centre de recherche en épidémiologie et santé des populations, UFR de médecine Simone-Veil, université de Versailles Saint-Quentin-en-Yvelines, hôpital Ambroise-Paré, Boulogne-Billancourt, AP–HP

DOI:

https://doi.org/10.3166/rea-2019-0112

Keywords:

Diaphragm, Ultrasound, Weaning

Abstract

Septic shock still places a burden to the healthcare systems worldwide owing to its high incidence and morbimortality. Recent international guidelines have suggested vasopressin as a second-line vasopressor therapy in norepinephrine-treated patients. Vasopressin is now broadly used in many countries in the routine management of septic shock. Vasopressin has received marketing authorization by the European medicine agency on May 31, 2018. Yet, recently, the French High Health Authority refused vasopressin registration in France. The current manuscript aimed at investigating the discrepancies in the interpretations of evidence-based data between the French High Health Authority and scientific societies that have endorsed the Surviving Sepsis Campaign guidelines.

Published

2019-07-01

How to Cite

Annane, D., Bollaert, P.-E., Demoule, A., Mira, J.-P., Monnet, X., Teboul, J.-L., & Vieillard-Baron, A. (2019). The High Health Authority Has Refused Access to Vasopressin for Septic Shock: Patients Are not Being Given the Best Possible Chance!. Médecine Intensive Réanimation, 28(4), 300–302. https://doi.org/10.3166/rea-2019-0112

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>